Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

The Just MS (Multiple Sclerosis) Show

The Just MS (Multiple Sclerosis) Show artwork

FDA Reviews Fenebrutinib, Remyelination Trial Begins & New MS Inflammation Target | Just MS News

Oct 6, 202615 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail This week in Just MS News, we cover three important developments across the MS research pipeline. The FDA has begun Priority Review of fenebrutinib for both relapsing MS and primary progressive MS, following three major Phase III trials. We also revisit PRO-1562, a remyelination therapy we’ve followed before, as it moves from preclinical research into its first Phase 1/2a human study. And researchers have identified a new inflammatory pathway involving HPGDS and PGD₂ that may help drive Th17-cell activity in MS. Human blood and cell findings supported the pathway, while blocking it reduced MS-like disease in mice. Also on the shortlist this week: • Continuing CAR-T safety questions in autoimmune trials • The 2026 Rachel Horne Prize recognizing research on women and MS • A&W Canada and MS Canada raising $1.56 million through Burgers to Beat MS As always, the goal is to separate what the research actually shows from what it does not - without hype or information overload. SOURCES & ARTICLES FDA Begins Priority Review of Fenebrutinib for Relapsing and Primary Progressive MS Source: BioPharma Dive https://www.biopharmadive.com/news/roche-fenebrutinib-ms-fda-accept-application-btk/831746/ Primary source: Roche https://www.roche.com/media/releases/med-cor-2026-09-30 PRO-1562 Enters First Phase 1/2a Human Study Focused on Remyelination Source: AllSci https://allsci.com/news/clinical-trials/pro-1562-multiple-sclerosis-trial-progentos/ Targeting the HPGDS-PGD₂ Axis to Treat Th17 Cell-Mediated Autoimmunity in Multiple Sclerosis Source: Signal Transduction and Targeted Therapy / Nature Portfolio https://www.nature.com/articles/s41392-026-02937-5 Autoimmune Researchers Seek Answers After Deaths in CAR-T Cell Trials Source: Medscape https://www.medscape.com/viewarticle/autoimmune-researchers-seek-answers-after-deaths-car-t-cell-2026a10010xi Recognising Excellence in Women’s MS Research - 2026 Rachel Horne Prize Source: MS Trust https://mstrust.org.uk/news/recognising-excellence-womens-ms-research A&W and MS Canada Celebrate $1.56 Million Raised Through Burgers to Beat MS Source: A&W Canada / MS Canada / Newswire https://www.newswire.ca/news-releases/a-amp-w-and-ms-canada-celebrate-outstanding-generosity-from-canadians-with-1-56-million-raised-from-burgers-to-beat-ms--899132706.html The Just MS (Multiple Sclerosis) Show, w host Justin Loizos, is a podcast that connects, educates and tries to uplift others living with multiple sclerosis. It provides real-life stories, interviews, and information about DMTs (disease modification therapies) and updates on research developments. www.justmultiplesclerosis.com

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. When MS Isn’t MS, a New Tablet’s Trial Results & Earlier Clues Just MS News

    Nov 4, 202618 minAudio

    Send us Fan Mail Nearly 20 years with an MS diagnosis - then a different answer. An experimental MS tablet raises questions about effectiveness and safety. And researchers investigate whether AI could help recognize MS...

    Credit the people on this episode

  2. Christina Applegate’s MS Diagnosis Questions, Remibrutinib Results & CAR-T Safety | Just MS News

    Oct 27, 202618 minAudio

    Send us Fan Mail Description This week on Just MS News: Christina Applegate’s reported MS misdiagnosis, detailed Phase 3 results for remibrutinib, and early CAR-T findings that raise serious safety questions. Join...

    Credit the people on this episode

  3. New Clues to MS Damage, GLP-1 Drug Research & Progression Beyond Relapses | Just MS News

    Oct 20, 202617 minAudio

    Send us Fan Mail How can we better understand MS damage - and recognise progression when relapses aren’t happening? This week on Just MS News, Justin Loizos explores new research into MS damage, GLP-1 drugs and...

    Credit the people on this episode

  4. Ocrevus: 10-Year Results, Myelin Repair Funding & MSToronto2026 | Just MS News

    Oct 13, 202613 minAudio

    Send us Fan Mail What can long-term treatment research tell us about living with MS - and what will it take to move myelin repair research forward? This week on Just MS News, Justin Loizos explores three stories...

    Credit the people on this episode

  5. Alpha-Lipoic Acid Advances | EBV Before Relapse, Ocrevus & CAR-T - Just MS News

    Sep 22, 202616 minAudio

    Send us Fan Mail This week in Just MS News: Alpha-lipoic acid has passed an important interim checkpoint in the phase 3 OCTOPUS trial for progressive MS, while metformin will not continue. This does not yet prove ALA...

    Credit the people on this episode